- RecruitingPHASE2
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
This study looks at a new drug, NX-5948, for adults with specific types of blood cancer (CLL or SLL) that have come back or not responded to previous treatments. It aims to see how well and how safely this new drug works.
For: Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL)United States · France · Italy - RecruitingPHASE1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
This study is testing a new medicine, NX-5948, for adults with certain types of blood cancer that have come back or not responded well to previous treatments. It aims to find out if the medicine is safe and helps fight the cancer, starting with small doses and gradually increasing.
For: Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL) · Diffuse Large B Cell Lymphoma (DLBCL)United States · France · Italy